MedWatch

Novo Nordisk after US delivery issues: New obesity drug launch set for H2 next year

It is not just in the US that significant demand for Novo Nordisk's obesity drug Wegovy is having an impact. The pharmaceutical firm now reports that new launches of the drug will not take place until during the second half of 2022.

Photo: Tidsvilde Stine/Ritzau Scanpix

Major US demand for obesity drug obesity Wegovy – which has led to delivery problems for Novo Nordisk – mean that the Danish pharmaceutical company will not begin new launches of the medication before a year's time at the earliest, Novo tells MedWatch in an email.

"We are currently assessing how we can increase production capacity and continue to global rollout following approval from public authorities outside the US. For the moment, the US is expected to take the accessible production capacity for Wegovy, and that means new launches will occur in the second half of 2022 at the earliest," the company's press unit writes.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs